Intranasal administration of peptide-tagged AELN/RNP complexes <i>in vivo</i> confirmed the successful genome editing of <i>C9orf72</i>, demonstrating the potential of this system for treating neurodegenerative diseases. Here, RNPC3 is linked to neurodegenerative disease.